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Every year around the world, the prevalence of obesity is increasing. Obesity and its associated 
diseases have become some of the most pressing health problems in developed and developing 
countries. In its development, adipocytes dysfunction and chronic low-grade inflammation occur in 
obesity will stimulate diseases at higher risk including type 2 diabetes mellitus (T2DM), 
atherosclerosis, hypertension, and metabolic syndrome. Western diet and sedentary lifestyle are 
thought to have significantly contributed to the increase in obesity recently. Diet modification is a 
sound method to prevent obesity and its complications. Nevertheless, the concern lies in the ratio 
of omega-6 towards omega-3 fatty acids intake, modern dietary habits induce transition of this ratio 
from 1-4:1 to 20:1 or higher. Omega-3 and omega-6 are two essential fatty acids that emerge as 
dominant factors in obesity through adiponectin. Adiponectin refers to a protein hormone 
conceived by adipocytes to prevent obesity and its subsequent complications by increasing insulin 
sensitivity, fatty acid oxidation, anti-inflammatory, and antiaterogenic. This study is a literature 
study with sources from journals and textbooks in the last ten years. This study aims to determine 
the role of fatty acids in omega-6 towards those within omega-3 by using adiponectin as the 
indicator of advancement to obesity and its underlying diseases. Several studies that examined the 
ratio of omega-6 to omega-3 fatty acids intake with adiponectin have shown inconsistent results 
may be due to dietary diversity and genetic factors in each population. Therefore, further studies 
in a more various population may be required. 
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Introduction 
 
Obesity is a global epidemic where more than 650 
million people are obese worldwide.1 In Indonesia, 
there has been an increase in obesity by 47.2% in the 
last five years. An estimated 50 trillion rupiah per 
year is spent on the costs of treating obesity and its 
subsequent complications such as T2DM, heart 
disease, stroke, metabolic syndrome, and  
 
atherosclerosis.2,3 Obesity occurs when there is an 
imbalance between the amount of input energy 
compared with the amount of energy that excreted in 
a long time. Western diet and sedentary lifestyle in 
today's lifestyle is one of the factors that cause an 
increase in obesity. In addition to physical activity, 
modification of dietary patterns is also essential for 
the prevention of obesity.4–6 
Prolonged overnutrition provokes adipocytes 
expansion resulting in adipocytes dysfunction, 
which is characterized by the increase of tumor 
necrosis factor (TNF) -a and interleukin (IL) -6, 
monocyte chemoattractant protein (MCP) -1, leptin, 
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and resistin. This condition prompts the 
accumulation of immune cells within fat or adipose 
tissue and chronic low-level inflammation.4,7,8 
Unlike other adipokines, which increase in obesity, 
the production of adiponectin is decreasing. 
Adiponectin is the most adipokines produced by 
adipocyte cells which have the effect of increasing 
insulin sensitivity, fatty acid oxidation, anti-
inflammatory, and antiaterogenic.9 Adiponectin is 
one indicator of the progression of obesity and its 
related diseases.10 Decreased production and 
secretion of adiponectin have even begun occuring 
in overweight conditions and once uncontrolled will 
worsen the obesity advancement.11 
Dietary patterns of fatty acids intake within 
omega-3 and omega-6 can also affect adiponectin 
levels.4,12,13 It is worth-mentioning that fatty acids 
within omega-3 and omega-6 fatty are essential to 
hold different roles with each other to adiponectin. 
In contrast to fatty acid within omega-3 which 
constitutes anti-inflammatory effects, the one that of 
omega-6 genuinely form an intertwined effect of 
proinflammation.14 Due to these two fatty acids 
compete with one another in metabolic processes, 
the intake ratio of fatty acid within omega-6 towards 
one that of omega-3 shall be maintained optimally. 
In contrast, in the present age of industrialization, 
unhealthy dietary patterns cause this ratio to become 
unbalanced.15 The role of the ratio between fatty 
acid in omega-6 towards one that of omega-3 in 
obesity, particularly in adiponectin, has not been put 
forward up to this point. Thus, this research aims to 
investigate the mechanism and the role of the intake 
ratio in omega-6 fatty acid towards the one that of 
omega-3 in adiponectin as an indicator of obesity 




Omega-3 and omega-6 fatty acids compete each 
other inside the body 
 
The investigation of fatty acids in the diet was 
commenced in 1929 by Burr when it was concluded 
that fatty acids in omega-3 are essential elements to 
prevent disease. Research on fatty acids continues to 
grow to date, particularly over its integral role in 
preventing and curing different types of diseases.16 
Omega-6 and omega-3 possess essential elements 
called polyunsaturated fatty acids (PUFAs); such 
acids are obtained from the diet. Furthermore, fatty 
acids within omega-6 are commonly identified as 
linoleic acid (LA) (18:2w-6) and fatty acids in 
omega-3 fatty are generally termed as alpha-
linolenic acid (ALA) (18:3w-3).17 Recommended 
dietary allowance of omega-3 fatty acid from 
Institute of Medicine (IOM) for male and female 
adults are 1,6 g/day and 1,1 g/day, respectively. 
While omega-6 fatty acid daily requirement is 17 
g/day for male and 12 g/day for female.18 Food 
sources that contain ALA the most obtained from 
fish, seafood, fish oil, different combinations of nuts 
and seeds including flaxseed and chia seed. Some 
fortified foods, such as meat and eggs, are also a 
source of ALA. While LA is found in many types of 
vegetable oils and their products (Table 1).19,20 
Both fatty acids will go through the 
metabolization process into long-chain fatty acids 
(LCFA) (20 and 22 carbon atoms) through the 
process of elongation (by adding two carbon atoms) 
and desaturation (through the addition of a double 
bond in between two carbon atoms) (Figure 1). 
Later, LA will be converted to arachidonic acid 
(AA) (20:4w-6), while ALA will go through 
conversion into eicosapentaenoic acid (EPA) 
(20:5w-3) and docosahexaenoic acid (DHA) 
(22:6w-3).15 Modifications of ALA into EPA and 
DHA occur are time-consuming processes as the 
cost of competing acids between LA and ALA in 
absorbing enzymes throughout the desaturation 
process; this desaturase enzyme is concealed by the 
fatty acid desaturase (FADS) gene. This enzyme is 
more likely to be used by ALA than LA. However, 
high LA intake, as in the Western diet, can disrupt 
desaturation and elongation from ALA.17 
 
The balance of omega-6 fatty acid intake ratio 
towards omega-3 fatty acid 
 
Fatty acids within omega-6 and omega-3 cannot be 
substituted with each other and have metabolic and 
functional differences. Both ALA and AA will 
produce eicosanoids as the final product that has the 
opposite effect. Eicosanoids, which are derived by 
AA, contribute to inflammatory diseases, including 
obesity and its complications. High diets in omega-
6 fatty acids cause a pro-inflammatory, 
prothrombotic, and proagregatory state, with 
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increased blood viscosity, vasospasm, 
vasoconstriction, and cell proliferation. On the other 
hand, ALA-derived eicosanoids have less potent 
inflammatory properties than AA-derived 
derivatives.7,17 The presence of competition in the 
use of enzymes in metabolic processes and end 
products that have opposite effects prompts a 
balance between the intake of these two fatty acids 
to be necessary. The recommended intake for 
omega-6 to omega-3 fatty acid ratio is 1-4:1. This 
ratio balance must be maintained optimally for the 
metabolic processes in the body to run normally.15 
Before the era of food industrialization in the 
20th century, researchers predicted that the ratio of 
fatty acids in omega-6 fatty towards those that of 
omega-3 in human food averaged between 1:1 and 
4:1. Along with the development of modern 
agricultural technology, there is a change in eating 
patterns manifested by the emergence of various 
processed foods. This shift in dietary patterns causes 
the ratio of fatty acid intake within omega-6 towards 
one that of omega-3 to experience a drastic change 
and reaches the highest ratio of all time, as such 
estimated to stand between 10:1 and 20:1, possibly 
even higher.17 The imbalance in the fatty acid intake 
ratio of Omega-6 towards one within Omega-3 is 
predicted to contribute to a surge of overweight and 
obesity prevalences toward adults in various 
populations.7 
 
The ratio of omega-6 fatty acid intake towards 
omega-3 and its effect on adiponectin 
 
In the case of obesity, fatty acids within omega-3 
and omega-6 play an integral role in impacting 
adiponectin production and secretion. Adipocyte 
dysfunction that occurs upon obesity chronically 
prompts a state of low-grade inflammation indicated 
by multiple inflammatory markers and adipokines 
inlcuding leptin and resistin. This inflammatory 
state also causes dysregulation of adiponectin.7,8,21 
Adiponectin (Acrp30/ADIPOQ) refers to a protein 
comprised of 244 amino acids with a 30 kDa load 
concealed by adipocytes. Adiponectin commonly 
tasked to increase glucose uptake, insulin sensitivity, 
and oxidation within cells’ fatty acids through two 
primary receptors; adiponectin receptor 1 
(AdipoR1) and adiponectin receptor 2 
(AdipoR2).22,23 Low adiponectin levels are 
associated with a higher risk of obesity and disease 
related to obesity. Conversely, high adiponectin 
levels work by elevating insulin sensitivity and 
oxidation with fat to prevent obesity and its 
complications. Adiponectin has been widely used as 
an examination indicator in monitoring the 
development and treatment of obesity.21 In 
adiponectin, fatty acids of omega-3 and omega-6 
perform differently through several mechanisms, 
particularly the process of adipogenesis, fat 
homeostasis, endocannabinoid, and systemic 
inflammation (Table 2). Therefore, the balance of 
the ratio between fatty acids in omega-6 and those 
of omega-3 essential with adiponectin.3,7 
In the process of adipogenesis and fat 
metabolism, fatty acids within omega-6 and omega-
3 perform as transcriptional factors to control the 
gene expression involved within the process of 
diversification of preadipocytes. Differentiation of 
preadipocytes into mature adipocytes is a vital 
process in the advancement of obesity. High levels 
of exogenous fat will fill fat particles in mature 
adipocytes. Mature adipocytes can no longer divide, 
resulting in hypertrophy and hyperplasia that 
induces adipocyte dysfunction in excess energy. 
Eicosanoid derivatives of omega-6 fatty acids, such 
as cyclooxygenase (COX), lipoxygenase (LOX), 
and prostacyclin are bound to prostacyclin receptors 
(IP-R) on the periphery of preadipocyte cells. Later 
the protein kinase A (PKA) pathway will be 
activated, which ultimately rules the expression of 
various peroxisome proliferators-activated receptors 
(PPARs) and results to adipogenesis.7,15,24 
Arachidonic acid metabolites such as 
prostaglandin (PG) I2 and PGF2 generate an 
increase in white adipose tissue and a downfall in 
brown adipose tissue. In contrast, ALA works to 
repress the adipogenic effects of LA through several 
mechanisms. The expression of COX2 messenger 
ribonucleid acid (mRNA) and the production of 
COX2 have been evidently inhibited by DHA. Later, 
EPA and DHA also work to obstruct the activity of 
COX1 and COX2. Prostaglandin effects emanating 
from AA-derived eicosanoids are also directly 
inhibited by ALA.7,15,24 Lastly, EPA and DHA can 
minimize the production of cyclic adenosine 3′,5′-
monophosphate (cAMP) or PKA catalyst subunits in 
the IP-R pathway. Aside from this inhibitory effect 
within adipogenesis, fatty acids of omega-3 also 
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alter lipid homeostasis by having the involved 
expression of genes suppressed in lipogenesis 
inclusive of fatty acid synthase, lipoprotein lipase 
and stearoyl-CoA desaturase-I and also increases the 
genes expression within β-oxidation including acyl-
CoA oxidase. The result is a reduction in body fat 
mass, especially in the liver, skeletal muscle, and 
adipose tissue.24 In adipose tissue, there is an 
improvement in adipocyte function which will affect 
increasing the production and secretion of 
adiponectin.13  
Other potential impacts of fatty acids in omega-3 
and omega-6 fatty toward adiponectin are also 
related to the fusion of the distinctive eicosanoids it 
produces. PGE2, PGI2, and tromboxan (TXA) 2 and 
4-grouping leukotrienes (LT) B4 generated from 
omega-6 fatty acids are potent pro-inflammatory 
agent. In contrast, prostaglandins 3-grouping 
(PGE3, PGI3, and TXA3) and 5-grouping LTB5 
formed from omega-3 fatty acids from the same 
enzyme are less pro-inflammatory. Also, the 
formation of E series of 5-LOX (E1 and E2) derived 
from EPA and resolvin, protectin, and maresin, 
which originated from DHA, has potent anti-
inflammatory characteristics. In animal studies, 
intake of omega-3 acids convincingly minimizes the 
expression of inflammatory markers including 
MCP-1, IL-6, interferon-γ (IFN-γ), and plasminogen 
activator inhibitor-1 (PAI-1). In human subjects, 
high diets in omega-3 massively shrinking the 
omega-6 ratio towards omega-3 in plasma, reduce 
the circulation of c-reactive protein (CRP), IL-6, 
TNF-α, MCP-1 levels, and the number of tissue 
macrophages adipose. Through the effect on 
decreasing the activation of these inflammatory 
markers, a balanced ratio of fatty acids in omega-6 
towards those of omega-3 can increase adiponectin 
secretion.7,15,17,24 
The expression and the concealment of 
adiponectin are also directly modulated by fatty 
acids of omega-3. As commonly mentioned in vitro 
studies, it is known that EPA and DHA act as natural 
ligands from peroxisome proliferator-activated 
receptor g (PPARγ). PPARγ is recognized to be an 
important regulator of adiponectin gene 
transcription. However, in contrast to DHA, which 
stimulates adiponectin secretion via the PPARγ 
channel exclusively, EPA is understood to have 
other additional mechanisms that are still unknown. 
This additional mechanism is thought to involve the 
activation of the 5’ adenosine monophosphate-
activated protein kinase (AMPK) enzyme in 
increasing adiponectin secretion.7,25  
Appetite regulation and energy balance are also 
influenced by fatty acids in omega-6 and omega-3. 
LA-derived endocannabinoid metabolism can 
stimulate appetite and lipogenesis in the liver 
through activation of its receptors in various tissues. 
While fatty acids within omega-3 reduce the 
production of endogenous endocannabinoids or 
decrease the sensitivity of their receptors, and also 
induce the production of other anorexia oxygenic 
neuropeptide neuropeptides in the hypothalamus, 
which serves to suppress appetite and lead to 
decreased energy intake. The decrease in energy 
intake will result in improved adipocyte function 
which affects increasing adiponectin production and 
secretion.7,17  
Several kinds of research examining the 
relationship between fatty acids in omega-3 and 
omega-6 fatty toward adiponectin have been 
performed (Table 3). A study that involved 44 
patients with dialysis, plasma adiponectin levels 
were found to be in progressive correlation with 
omega-3 fatty acids (r=0.58) and inversely related to 
fatty acids of omega-6 (r=-0.64), both of which 
statistically significant (p<0.01).27 A meta-analysis 
investigation inferred that intake of fatty acids in 
omega-3 particularly those obtained from high dose 
supplementation (>2 g) can boost the levels of 
adiponectin in prediabetes and T2DM patients. 
However, the heterogeneity of results in these 
studies is still very high.32 Yang et al. also, in his 
research on subjects with polycystic ovary 
syndrome, show increased levels of adiponectin 
(p=0.002) after administration of omega-3 fatty 
acids with varying doses (900-4000 mg) compared 
with placebo.33 Similar results were also obtained by 
studies in non-alcoholic fatty liver disease (NAFLD) 
patients who were given capsules of fish oil whose 
containment embodies the benefit of EPA 182 mg 
and DHA 129 mg twice daily for three months 
showed a significant boost in adiponectin levels (p 
<0.001).28 
In contrast to the results of the studies above, an 
individual investigation deliberated by Sabour et al. 
show results that an absence of visible development 
was indicated in adiponectin levels within the 
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regulation of fatty acids of omega-3 in 14 months 
timespan towards patients with spinal cord injury.29 
Torres-Castillo et al., in his research on subjects 
aged 18-65 years with BMI ≥18.5 kg/m2, show that 
adiponectin levels showed a decreasing trend when 
the ratio of fatty acids intake between omega-6 
toward those of omega-3 was increased. However, 
this difference has not statistically significant 
(p=0.061 ).12 The administration of high omega-3 
diets for six months in T2DM patients also showed 
no contrasting difference compared to the control 
group.31 Studies on supplementing fatty acids in 
omega-3 with lifestyle modification for 12 weeks in 
female subjects with overweight also did not provide 
a significant increase in adiponectin levels compared 
to the control group.30 Identical findings were 
revealed by Jacobo-Cejudo et al. in his study of 
T2DM patients, where no significant difference in 
adiponectin levels was found after six months of 
supplementation towards fatty acids within omega-
3 when compared to placebo.31 
Studies that examined the ratio of fatty acids 
intake in omega-6 toward those of omega-3 with 
adiponectin levels have not been widely examined 
and show different results. The diversity of the 
population remains limited, whereas it is understood 
that one's environment strongly influences a person's 
dietary patterns. Each population has different 
characteristics of dietary patterns, including food 
sources within intake ratio of fatty acids between 
both omega-6 and omega-3.3,24 Population 
differences also affect the metabolic processes of 
these two types of fatty acids. The metabolism 
process of these fatty acids in omega-3 and omega-
6 is acknowledged to be influenced by genetic 
variations of the FADS enzyme, which can provoke 
differences in the rate metabolism towards these 
fatty acids and the composition of those in plasma.35 
The ADIPOQ gene polymorphism has also probably 
played a part in the various findings of these studies. 
Genetic variations of ADIPOQ may be influence 
different response of adiponectin gene to these two 
fatty acids.36 Interactions among genetic factors and 
dietary patterns in diverse populations will lead to 
someone's different risks against obesity seen from 






Fatty acids contained within omega-3 and omega-6 
are essential compounds that have different 
functions from one another to adiponectin. Both 
types of fatty acids in omega-3 and omega-6 perform 
an integral role in adiponectin through the process of 
adipogenesis, fat homeostasis, endocannabinoids, 
and systemic inflammation. The balanced ratio 
between these two fatty acids can increase 
adiponectin levels to hold prominence in the 
prevention of obesity and its underlying diseases. 
Previous researches that examined the ratio of fatty 
acids intake from omega-6 to omega-3 with 
adiponectin levels is still limited, and the results 
have not been consistent; this is considered to be 
prompted by dietary diversity and genetic factors in 
each population. Modification of omega-6 to 
omega-3 fatty acid intake ratio on diet potentially 
against obesity through adiponectin regulation. 
However, further research on the relationship 
between the ratio of fatty acids intake from omega-
6 to omega-3 with adiponectin in a more diverse 











Figure 1. Desaturation and Elongation Process of Omega-3 and 
Omega-6 Fatty Acid15 
Additional information: AA: arachidonic acid; ALA: alpha-linolenic 
acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; 
FADS1: fatty acid desaturase 1; FADS2: fatty acid desaturase 2; 
GLA: gamma-linolenic acid; LA: linoleic acid. 
Table 1. Omega-3 and omega-6 fatty acid food sources19,20 

















































































Table 2. The role of omega-6 and omega-3 fatty acids to adiponectin7,15 
 
Mechanism Omega-6 Fatty Acid Omega-3 Fatty Acids 
Adipogenesis - COX activates the PKA pathway 
- COX and LOX Increase PPAR 
gene expression leading to 
adipogenesis 
- Reducing mRNA expression and 
COX-2 production 
- Restrains the effect of omega-6 
fatty acid metabolites directly 
- Reducing the production of cAMP 
or PKA subunits 
Fat metabolism - Increase triglyceride content - Decreases gene expression 
associated with lipogenesis 
- Increases genes expression of 
oxidation-b related   
Inflammation - Increase the production of 
inflammatory markers 
- Prevents inflammation 
Endocannabinoid - Increase appetite and energy intake 
 
- Reduces the production of 
endocannabinoids and their 
receptor sensitivity 
- Stimulates proopiomelanocortin 
- Activating PPARg and AMPK 
pathways 
Additional information: AMPK: 5’ adenosine monophosphate-activated protein kinase; cAMP: cyclic adenosine 
3′,5′-monophosphate; COX: cyclooxygenase; LOX: lipoxygenase; mRNA: messenger ribonucleic acid; PKA: protein 
kinase A; PPAR: peroxisome proliferators-activated receptor; PPARg: peroxisome proliferator-activated receptor g. 
 
 
Table 3. Characteristics of the studies that examined omega-3 and omega-6 fatty acids with adiponectin 
 
Author Study Design Subjects Results/ Conclusion 




73 dialysis patients and 
10 healthy subjects 
Plasma adiponectin was associated 
with erythrocyte omega-3 fatty acid 
(r=0.581, p=0.023) and inversely 
associated with omega-6 fatty acid 
(r=–0.640, p=0.010) in the dialysis 
patients 





80 NAFLD associated 
with hyperlipidemia 
patients; trial group=40, 
control group=40 
Administration of fish oil capsules 
(EPA 182 mg; DHA 129 mg) twice 
daily in 12 weeks showed increased 
levels of adiponectin compared with 
control group (p<0.001) 





104 spinal cord injury 
patients; trial group=54; 
control group=50 
No significant differences in 
adiponectin between groups after 
administration of omega-3 fatty acids 
capsules (DHA 465 mg; EPA 63 mg) 
for 14 months 





35 T2DM patients; trial 
group=19, control 
group=16 
No significant difference in 
adiponectin between groups after 
administration of high omega-3 diets 
for 6 months 
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